Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carfilzomib for Inj 60 milligram · 1 trial · 1 indication
The proportion of patients having achieved at least partial response.
| Arm | Type | Description |
|---|---|---|
| Carfilzomib, elotuzumab, dexamethasone | EXPERIMENTAL | Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv) |
| Name | Type | Description |
|---|---|---|
| Carfilzomib for Inj 60 milligram (MG) | DRUG | All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone |
| Elotuzumab 400 MG | DRUG | All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone |
| Dexamethasone | DRUG | All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone |
Inclusion Criteria: 1. Male or female patients at the age of 18 to below 75 years with the life expectancy of at least three months. 2. Prior confirmed diagnosis of multiple myeloma and measurable disease in blood or urine with at least one of the following: Serum M-protein ≥ 5g/l, Urine M-protein ...
Carfilzomib for Inj 60 milligram is an injectable small molecule being studied for relapsed multiple myeloma. It is given in combination with elotuzumab and dexamethasone in patients who have received one to three prior lines of treatment. The asset is in Phase 2 clinical development.
Carfilzomib for Inj 60 milligram targets the proteasome subunits PSMD1, PSMB2, PSMB1, PSMB5, PSMB8, and PSMB9. It acts as an inhibitor of these targets, which are part of the ubiquitin-proteasome system involved in protein degradation within cells.
Carfilzomib for Inj 60 milligram is being developed by Amgen Inc., which trades under the ticker AMGN. Amgen is the company responsible for the clinical program of this asset.
Carfilzomib for Inj 60 milligram is in Phase 2 clinical development. It is investigational and has not been approved by the FDA for any indication. The program includes one completed Phase 2 trial.
Carfilzomib for Inj 60 milligram has been studied in one completed Phase 2 trial, NCT03155100, titled Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines. The trial enrolled 15 patients in Finland and Sweden and is now completed.